Comparative Effectiveness of Different Antiplatelet Regimens in Patients with Acute Coronary Syndrome: A Systematic Review

Simple item page
dc.contributor.authorMesfin, KHen_US
dc.contributor.authorObi, MOen_US
dc.contributor.authorOdugunwa, MNen_US
dc.contributor.authorChilaka, MUen_US
dc.contributor.authorGoswami, Ren_US
dc.contributor.authorIwuagwu, Men_US
dc.contributor.authorMendha, AAen_US
dc.contributor.authorMejia, IVen_US
dc.contributor.authorEhimwenma, Nen_US
dc.contributor.authorAguda, Ken_US
dc.contributor.authorGopal, Sen_US
dc.contributor.authorOhwodo, OFen_US
dc.contributor.authorWaithaka, FWen_US
dc.contributor.authorEzewudo, Oen_US
dc.contributor.authorAzipu, Ren_US
dc.contributor.authorEchere, J.en_US
dc.date.accessioned2024-11-30T08:52:07Z
dc.date.available2024-11-30T08:52:07Z
dc.date.issued2024-08
dc.description.abstractAcute coronary syndrome (ACS) remains a leading cause of morbidity and mortality worldwide. The accumulation of platelets is central to the development and pathogenesis of ACS, making antiplatelet therapy a cornerstone in its management. This review aims to assess the effectiveness of various antiplatelet therapies in patients with ACS. The methodology for this review adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A total of 38 studies from the past decade were included, with articles sourced from Google Scholar and PubMed. The findings indicate that traditional antiplatelet agents, such as aspirin and clopidogrel, have been extensively utilized in the treatment of ACS. Despite their benefits, these agents are limited by a slow onset of action, variable efficacy, and relatively low antiplatelet potency. These limitations have been addressed by the development of newer antiplatelet agents, such as rivaroxaban, ticagrelor, and prasugrel, which offer more potent and predictable platelet inhibition. These novel agents have demonstrated a significant reduction in stent thrombosis, major adverse cardiac or cerebral events (MACCE), and mortality rates in patients with ACS. However, they are associated with an increased risk of severe bleeding in some cases. Another approach, dual antiplatelet therapy (DAPT), which involves the combination of different antiplatelet agents, has shown enhanced safety and efficacy in the management of ACS patients. In conclusion, the effectiveness of antiplatelet therapies is influenced by individual patient characteristics and risk factors. Striking the right balance between reducing the risk of major cardiovascular events and minimizing the potential for severe bleeding remains a critical challenge. Further research is needed to refine our treatment strategies for patients with ACS.en_US
dc.identifier.affiliationsAyder Comprehensive Specialized Hospital, Ethiopiaen_US
dc.identifier.affiliationsMadonna University College of Medicine, Nigeriaen_US
dc.identifier.affiliationsAmerican University of Antigua College of Medicine (AUACOM), Antigua & Barbudaen_US
dc.identifier.affiliationsChukwuemeka Odumegwu Ojukwu University College of Medical Sciences, Nigeriaen_US
dc.identifier.affiliationsAmerican University of Antigua College of Medicine (AUACOM), Antigua & Barbudaen_US
dc.identifier.affiliationsAll Saints University School of Medicine, Dominicaen_US
dc.identifier.affiliationsGrodno State Medical University, Belarusen_US
dc.identifier.affiliationsUniversidad Libre, Barranquilla, Colombiaen_US
dc.identifier.affiliationsKharkiv National Medical University, Ukraineen_US
dc.identifier.affiliationsObafemi Awolowo University College of Health Sciences, Nigeriaen_US
dc.identifier.affiliationsBassett Medical Center, USAen_US
dc.identifier.affiliationsAmerican University of Barbados, School of Medicine (AUB), Barbadosen_US
dc.identifier.affiliationsAmerican University of Antigua College of Medicine (AUACOM), Antigua & Barbudaen_US
dc.identifier.affiliationsCollege of Medicine, University of Nigeria, Nigeriaen_US
dc.identifier.affiliationsUniversity of Calabar College of Medical Sciences, Nigeriaen_US
dc.identifier.affiliationsThe University of Texas Health Science Center at Houston School of Public Health, USA.en_US
dc.identifier.citationMesfin KH, Obi MO, Odugunwa MN, Chilaka MU, Goswami R, Iwuagwu M, Mendha AA, Mejia IV, Ehimwenma N, Aguda K, Gopal S, Ohwodo OF, Waithaka FW, Ezewudo O, Azipu R, Echere J.. Comparative Effectiveness of Different Antiplatelet Regimens in Patients with Acute Coronary Syndrome: A Systematic Review. Journal of Advances in Medicine and Medical Research. 2024 Aug; 36(9): 33-44en_US
dc.identifier.issn2456-8899
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/237247
dc.languageenen_US
dc.publisherMs. M. B. Mondalen_US
dc.relation.issuenumber9en_US
dc.relation.volume36en_US
dc.source.urihttps://doi.org/10.9734/jammr/2024/v36i95555en_US
dc.subjectAcute coronary syndromeen_US
dc.subjectplatelet aggregation inhibitorsen_US
dc.subjectcomparative effectiveness researchen_US
dc.subjectdrug therapyen_US
dc.subjectcombination monotherapyen_US
dc.subjectaspirinen_US
dc.subjectclopidogrelen_US
dc.subjectticagreloren_US
dc.subjectprasugrel hydrochlorideen_US
dc.subjectcardiovascular diseasesen_US
dc.titleComparative Effectiveness of Different Antiplatelet Regimens in Patients with Acute Coronary Syndrome: A Systematic Reviewen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
jammr2024v36n9p33.pdf
Size:
363.95 KB
Format:
Adobe Portable Document Format
Download
Collections
Journal of Advances in Medicine and Medical Research